Breast Cancer Profiling Project, Drug Sensitivity phase II: Fixed-cell GR measures of 33 breast cell lines and PDX lines to 16 small molecule perturbagens from library plate II. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20354)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration (uM) | Mean Normalized Growth Rate Inhibition Value | Increased Fraction Dead |
|---|---|---|---|---|
| CAL-85-1 | MK 1775 | 10.0 | -0.5298 | 0.37240 |
| CAL-85-1 | THZ1 | 1.0 | -0.5032 | 0.37632 |
| HME1 | Ulixertinib | 10.0 | 0.0167 | 0.37968 |
| HME1 | Ulixertinib | 10.0 | 0.0078 | 0.37986 |
| MCF 10A | LY3023414 | 3.16227766017 | 0.0431 | 0.38049 |
| HME1 | BMS-265246 | 3.16227766 | -0.0547 | 0.38150 |
| SUM159PT | MK 1775 | 10.0 | -0.1288 | 0.38197 |
| SUM1315MO2 | Alvocidib | 1.0 | -0.7885 | 0.38253 |
| HME1 | THZ1 | 0.316227766 | -0.2065 | 0.38302 |
| HME1 | RO-3306 | 10.0 | -0.0172 | 0.38377 |
| SUM149PT | THZ1 | 0.316227766 | -0.3148 | 0.38387 |
| SUM149PT | AZD6738 | 10.0 | -0.2224 | 0.38785 |
| MDA-MB-468 | MK 1775 | 10.0 | -0.5155 | 0.38863 |
| HCC38 | Alvocidib | 1.0 | -0.4394 | 0.38884 |
| AU565 | THZ531 | 1.0 | -0.4000 | 0.38913 |
| HCC38 | MK 1775 | 10.0 | -0.4785 | 0.38923 |
| MDA-MB-231 | Alvocidib | 1.0 | -0.3881 | 0.39015 |
| MDA-MB-453 | LY3023414 | 10.0 | -0.6182 | 0.39060 |
| SUM159PT | MK 1775 | 10.0 | -0.1602 | 0.39160 |
| HCC70 | MK 1775 | 10.0 | -0.7085 | 0.39220 |
| HCC70 | LY3023414 | 10.0 | -0.6575 | 0.39235 |
| AU565 | RO-3306 | 10.0 | -0.2121 | 0.39266 |
| BT-549 | THZ531 | 1.0 | -0.3492 | 0.39325 |
| SUM149PT | MK 1775 | 10.0 | -0.3637 | 0.39408 |
| HME1 | RO-3306 | 10.0 | 0.0698 | 0.39559 |